Table 2.

Immunologic outcomes reported in people naive to antiretroviral therapy initiating dolutegravir + lamivudine by cohort and lead study.

Cohort lead study (substudy)	People naive to ART using DTG + 3TC	Time point, wk*	Median (IQR)* baseline CD4+ cell count, cells/mm3	Median (IQR)* CD4+ cell count at time point, cells/mm3
Dou et al[26]	96	4	174 (63–346)	+82 from baseline
		12		+138 from baseline
		24		+166 from baseline
(Li et al)[34]	77	48	278 (141–453)	+149 (68–231) from baseline (P < .001)
Hou et al[33]	46	48	312 (224–257)	+455 (262–661) from baseline (P < .05)
Hui et al[28]	54†	24	249 (118–310)	+128 (85–194) from baseline (<200 cells/mm3 at baseline: +130 [46–207])
Inan et al[60]	56	24	Mean (SD): 376 (210)	Mean (SD): 624 (307)
		48		Mean (SD): 721 (340)
Long et al[43] (Tu et al)[38]	33	8	VL < 500,000 copies/mL: 237 VL ≥ 500,000 copies/mL: 106	VL < 500,000 copies/mL: 295 (P < .05) VL ≥ 500,000 copies/mL: 250 (P < .05)
		24		VL < 500,000 copies/mL: 274 (P < .05) VL ≥ 500,000 copies/mL: 219 (P < .05)
(Long et al)[36]	107	48	257 (149–302)	Significant increase from baseline (z = −2.197; P = .03)
(Long et al)[35]	11	96	─	+119 from baseline (P = .05)
Wei et al[39]	200	12	285 (141–433)	364 (210–599) (P < .001)
		24		414 (318–673) (P < .001)
Zhao et al[29]	42	48	59 (27–178)	Mean (SD) change from baseline: VL < 500,000 copies/mL: +218 (122) VL ≥ 500,000 copies/mL: +265 (127)
Basova et al[65]	11	Mo 12	─	+243 from baseline
Lee et al[67]	20	Mo 6	446 (294–561)	620 (421–888) (P < .001 via repeated-measure ANOVA)
		Mo 12		667 (508–912) (P < .001 via repeated-measure ANOVA)
Ling et al[27]	14	48	Mean (SD): 202 (191)	Mean (SD): 323 (190) (P = .01)

─ = no data, 3TC = lamivudine, ANOVA = analysis of variance, ART = antiretroviral therapy, DTG = dolutegravir, VL = viral load.

^*Unless otherwise specified.

^†n = 21 included in analysis.